272 related articles for article (PubMed ID: 32906709)
1. Phenoconversion of Cytochrome P450 Metabolism: A Systematic Review.
Klomp SD; Manson ML; Guchelaar HJ; Swen JJ
J Clin Med; 2020 Sep; 9(9):. PubMed ID: 32906709
[TBL] [Abstract][Full Text] [Related]
2. CYP2D6 pharmacogenetics and phenoconversion in personalized medicine.
Nahid NA; Johnson JA
Expert Opin Drug Metab Toxicol; 2022 Nov; 18(11):769-785. PubMed ID: 36597259
[TBL] [Abstract][Full Text] [Related]
3. Addressing phenoconversion: the Achilles' heel of personalized medicine.
Shah RR; Smith RL
Br J Clin Pharmacol; 2015 Feb; 79(2):222-40. PubMed ID: 24913012
[TBL] [Abstract][Full Text] [Related]
4. The Evaluation of
Giorgetti A; Amurri S; Fazio G; Bini C; Anniballi L; Pirani F; Pelletti G; Pelotti S
Metabolites; 2023 May; 13(5):. PubMed ID: 37233702
[TBL] [Abstract][Full Text] [Related]
5. Cytochrome P450 2D6 phenoconversion is common in patients being treated for depression: implications for personalized medicine.
Preskorn SH; Kane CP; Lobello K; Nichols AI; Fayyad R; Buckley G; Focht K; Guico-Pabia CJ
J Clin Psychiatry; 2013 Jun; 74(6):614-21. PubMed ID: 23541126
[TBL] [Abstract][Full Text] [Related]
6. Pitfalls and challenges associated with phenoconversion in forensic toxcicology.
Drevin G; Picard N; Jousset N; Briet M; Abbara C
Forensic Sci Int Genet; 2021 Mar; 51():102433. PubMed ID: 33278816
[TBL] [Abstract][Full Text] [Related]
7. An analysis of allele, genotype and phenotype frequencies, actionable pharmacogenomic (PGx) variants and phenoconversion in 5408 Australian patients genotyped for CYP2D6, CYP2C19, CYP2C9 and VKORC1 genes.
Mostafa S; Kirkpatrick CMJ; Byron K; Sheffield L
J Neural Transm (Vienna); 2019 Jan; 126(1):5-18. PubMed ID: 30191366
[TBL] [Abstract][Full Text] [Related]
8. Inflammation-induced phenoconversion of polymorphic drug metabolizing enzymes: hypothesis with implications for personalized medicine.
Shah RR; Smith RL
Drug Metab Dispos; 2015 Mar; 43(3):400-10. PubMed ID: 25519488
[TBL] [Abstract][Full Text] [Related]
9. The impact of
de Jong LM; Boussallami S; Sánchez-López E; Giera M; Tushuizen ME; Hoekstra M; Hawinkels LJAC; Rissmann R; Swen JJ; Manson ML
Front Pharmacol; 2023; 14():1201906. PubMed ID: 37361233
[No Abstract] [Full Text] [Related]
10. Pharmacist-Led Medication Evaluation Considering Pharmacogenomics and Drug-Induced Phenoconversion in the Treatment of Multiple Comorbidities: A Case Report.
Del Toro-Pagán NM; Matos A; Thacker D; Turgeon J; Amin NS; Michaud V
Medicina (Kaunas); 2021 Sep; 57(9):. PubMed ID: 34577878
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenetics and phenoconversion: the influence on side effects experienced by psychiatric patients.
den Uil MG; Hut HW; Wagelaar KR; Abdullah-Koolmees H; Cahn W; Wilting I; Deneer VHM
Front Genet; 2023; 14():1249164. PubMed ID: 37693320
[No Abstract] [Full Text] [Related]
12. How to Integrate CYP2D6 Phenoconversion Into Clinical Pharmacogenetics: A Tutorial.
Cicali EJ; Elchynski AL; Cook KJ; Houder JT; Thomas CD; Smith DM; Elsey A; Johnson JA; Cavallari LH; Wiisanen K
Clin Pharmacol Ther; 2021 Sep; 110(3):677-687. PubMed ID: 34231197
[TBL] [Abstract][Full Text] [Related]
13. Distinct Effects of Inflammation on Cytochrome P450 Regulation and Drug Metabolism: Lessons from Experimental Models and a Potential Role for Pharmacogenetics.
de Jong LM; Jiskoot W; Swen JJ; Manson ML
Genes (Basel); 2020 Dec; 11(12):. PubMed ID: 33339226
[TBL] [Abstract][Full Text] [Related]
14. To Genotype or Phenotype for Personalized Medicine? CYP450 Drug Metabolizing Enzyme Genotype-Phenotype Concordance and Discordance in the Ecuadorian Population.
De Andrés F; Terán S; Hernández F; Terán E; LLerena A
OMICS; 2016 Dec; 20(12):699-710. PubMed ID: 27849442
[TBL] [Abstract][Full Text] [Related]
15. CYP2C19 Phenoconversion by Routinely Prescribed Proton Pump Inhibitors Omeprazole and Esomeprazole: Clinical Implications for Personalized Medicine.
Klieber M; Oberacher H; Hofstaetter S; Beer B; Neururer M; Amann A; Alber H; Modak A
J Pharmacol Exp Ther; 2015 Sep; 354(3):426-30. PubMed ID: 26159874
[TBL] [Abstract][Full Text] [Related]
16. The AmpliChip CYP450 genotyping test: Integrating a new clinical tool.
de Leon J; Susce MT; Murray-Carmichael E
Mol Diagn Ther; 2006; 10(3):135-51. PubMed ID: 16771600
[TBL] [Abstract][Full Text] [Related]
17. Chronic Inflammatory Status Observed in Patients with Type 2 Diabetes Induces Modulation of Cytochrome P450 Expression and Activity.
Darakjian L; Deodhar M; Turgeon J; Michaud V
Int J Mol Sci; 2021 May; 22(9):. PubMed ID: 34067027
[TBL] [Abstract][Full Text] [Related]
18. Quantifying the Impact of Phenoconversion on Medications With Actionable Pharmacogenomic Guideline Recommendations in an Acute Aged Persons Mental Health Setting.
Mostafa S; Polasek TM; Sheffield LJ; Huppert D; Kirkpatrick CMJ
Front Psychiatry; 2021; 12():724170. PubMed ID: 34489765
[No Abstract] [Full Text] [Related]
19. Combination of CYP2C19 genotype with non-genetic factors evoking phenoconversion improves phenotype prediction.
Kiss ÁF; Vaskó D; Déri MT; Tóth K; Monostory K
Pharmacol Rep; 2018 Jun; 70(3):525-532. PubMed ID: 29665549
[TBL] [Abstract][Full Text] [Related]
20. CYP450 Genotype/Phenotype Concordance in Mexican Amerindian Indigenous Populations-Where to from Here for Global Precision Medicine?
de Andrés F; Sosa-Macías M; Ramos BPL; Naranjo MG; LLerena A
OMICS; 2017 Sep; 21(9):509-519. PubMed ID: 28873029
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
